Antimicrobial Efficacy in Gram-Positive Bacterial Infections

Gram-positive bacteria, including Staphylococcus, Streptococcus and Enterococcus species, are responsible for a wide range of human infections from skin and soft tissue to life-threatening pneumonia and endocarditis. The efficacy of antimicrobial agents against these pathogens is under constant threat from emerging resistance mechanisms such as altered penicillin-binding proteins, efflux pumps and biofilm formation. Recent innovations span the development of novel β-lactams, lipoglycopeptides and oxazolidinones, each offering improved potency, pharmacokinetic profiles and safety. Clinicians now have access to antibiotics with extended half-lives permitting once-daily dosing, as well as agents capable of penetrating biofilms and targeting multidrug-resistant strains. Concurrently, sophisticated pharmacokinetic/pharmacodynamic (PK/PD) modelling and Monte Carlo simulations are refining dosing regimens to maximise probabilities of target attainment while minimising toxicity and resistance selection. Globally, these advances promise shorter hospital stays, reduced healthcare costs and improved outcomes, although the durability of new agents will depend on vigilant stewardship and continued surveillance.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Antimicrobial Efficacy in Gram-Positive Bacterial Infections publication trend

The graph below shows the total number of articles in antimicrobial efficacy in gram-positive bacterial infections across all publications each year (not limited to Nature Index journals).

Technical terms

Gram-positive bacteria: Bacteria with thick peptidoglycan cell walls that retain crystal violet stain and include key human pathogens.

Minimum inhibitory concentration (MIC): The lowest antibiotic concentration that prevents visible bacterial growth in vitro.

Pharmacokinetics/pharmacodynamics (PK/PD): The relationship between drug concentrations over time and their antimicrobial effects.

Methicillin-resistant Staphylococcus aureus (MRSA): A strain of S. aureus that has acquired resistance to β-lactam antibiotics via altered penicillin-binding protein.

Probability of target attainment (PTA): The likelihood that a dosing regimen will achieve the PK/PD exposure required to inhibit a pathogen.

References

1. New Antibiotics for Staphylococcus aureus Infection: An Update from the World Association of Infectious Diseases and Immunological Disorders (WAidid) and the Italian Society of Anti-Infective Therapy (SITA). Antibiotics (2023).
2. Population Pharmacokinetic and Pharmacodynamic Analysis for Maximizing the Effectiveness of Ceftobiprole in the Treatment of Severe Methicillin-Resistant Staphylococcal Infections. Microorganisms (2023).
3. Antibacterial activity of recently approved antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) strains: A systematic review and meta-analysis. Annals of Clinical Microbiology and Antimicrobials (2022).